State Street Corp Sells 18,700 Shares of PDS Biotechnology Co. (NASDAQ:PDSB)

State Street Corp decreased its holdings in PDS Biotechnology Co. (NASDAQ:PDSB) by 14.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 111,833 shares of the company’s stock after selling 18,700 shares during the period. State Street Corp’s holdings in PDS Biotechnology were worth $427,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Vontobel Holding Ltd. increased its holdings in PDS Biotechnology by 233.3% in the 3rd quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company’s stock worth $153,000 after buying an additional 28,000 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of PDS Biotechnology during the 2nd quarter valued at about $146,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of PDS Biotechnology in the second quarter worth approximately $115,000. Squarepoint Ops LLC purchased a new position in shares of PDS Biotechnology during the second quarter valued at approximately $120,000. Finally, Blair William & Co. IL lifted its position in PDS Biotechnology by 204.4% during the second quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after purchasing an additional 81,743 shares during the period. Hedge funds and other institutional investors own 26.84% of the company’s stock.

Wall Street Analyst Weigh In

PDSB has been the subject of a number of research analyst reports. StockNews.com downgraded shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. B. Riley reduced their price objective on PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, November 25th. Finally, HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $11.67.

PDS Biotechnology Stock Up 4.0 %

PDSB opened at $1.80 on Friday. The firm’s 50 day simple moving average is $2.30 and its two-hundred day simple moving average is $2.95. The company has a market capitalization of $67.34 million, a PE ratio of -1.55 and a beta of 1.85. PDS Biotechnology Co. has a 1-year low of $1.53 and a 1-year high of $6.68. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55.

PDS Biotechnology Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.